Switching antiretroviral regimes for the treatment of HIV: safety implications.

about

Reasons for switching ART: Comparison of data collected in 2012-2013 and 2014-2015 in Florence, Italy.Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.

P2860

Q38602419-907A7504-4F58-4F46-872E-A65BF8499A8F Q47142890-7641EF60-2C6F-42A3-BDDD-A54F594181BD

P2860

Switching antiretroviral regimes for the treatment of HIV: safety implications.

Item

http://www.wikidata.org/entity/Q38879406

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Switching antiretroviral regimes for the treatment of HIV: safety implications.

@en

type

Item

label

Switching antiretroviral regimes for the treatment of HIV: safety implications.

@en

prefLabel

Switching antiretroviral regimes for the treatment of HIV: safety implications.

@en

P1476

Switching antiretroviral regimes for the treatment of HIV: safety implications.

@en

P2093

Laia Utrillo

http://www.w3.org/2001/XMLSchema#string

Pere Domingo

http://www.w3.org/2001/XMLSchema#string

Teresa Puig

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

P304

1349-1360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2016.1206076

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesc Vidal

P577

2016-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27351491

http://www.w3.org/2001/XMLSchema#string

Switching antiretroviral regimes for the treatment of HIV: safety implications.

about

P2860

P2860

Switching antiretroviral regimes for the treatment of HIV: safety implications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698